Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.
Abbott rolled out its first over-the-counter glucose sensor in the U.S. on Thursday, just over one week after Dexcom began selling its competing product. The device, called Lingo, is intended to be ...
In April, a Securities and Exchange Commission filing revealed that Wojcicki planned to take the company private. 23andMe’s stock price had fallen below $1 per share at the time, down from its $10 ...